lead plaintiff deadline

Securities class action filed against $RARE over alleged misstatements about setrusumab drug efficacy. Failed clinical trials triggered 25-42% stock declines. Investor deadline: April 6, 2026.

Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors must claim lead plaintiff status by May 5, 2026.

Class action lawsuit filed against $NAAM alleges October 2025 IPO prospectus contained false statements about sales and marketing expenses. Lead plaintiff deadline: April 24, 2026.

Rosen Law Firm urges MREO investors to join class action over alleged misleading statements regarding setrusumab Phase 3 trial failures.

Rosen Law Firm urges Masonite investors to join class action lawsuit alleging material omissions regarding Owens Corning acquisition and share repurchases.

NuScale Power faces securities lawsuit alleging misrepresentations about commercialization partner ENTRA1's nuclear experience. Lead plaintiff deadline: April 20, 2026.

Rosen Law Firm files securities class actions against Nektar Therapeutics, Enphase Energy, and Aquestive Therapeutics. Investors have until May 5, 2026 to join.

Rosen Law Firm filed securities class action against Enphase Energy ($ENPH) alleging false statements on inventory and renewable energy credits. Deadline April 20, 2026.

Class action lawsuit filed against $METC alleges executives made false statements about Brook Mine development progress. Investors from July-October 2025 urged to participate.

Class action lawsuit filed against $APO alleging leadership made false statements about Jeffrey Epstein business dealings. Eligible investors purchased securities between May 2021 and February 2026.

REGENXBIO faces securities lawsuit over alleged misleading RGX-111 gene therapy statements. Lead plaintiff deadline is April 14, 2026.

Rosen Law Firm urges $BBWI investors to join class action by March 16, 2026 deadline, alleging materially false statements about business strategy and unmet financial guidance.

Rosen Law Firm solicits Beyond Meat investors from Feb-Nov 2025 for class action alleging material asset value misstatements and impairment disclosure failures.

BellRing Brands faces securities lawsuit alleging it misrepresented sales growth as organic when driven by inventory stockpiling, with a March 23, 2026 deadline for investors to join.

Rosen Law Firm alerts $SNOW investors of April 27, 2026 deadline in class action alleging undisclosed negative impacts from product efficiency gains.

uniQure faces securities lawsuit after FDA rejected AMT-130 approval pathway. Stock plummeted 49% following disclosure. Lead plaintiff deadline: April 13, 2026.

Kyndryl Holdings faces securities class action over undisclosed internal control weaknesses. Stock plunged 55% after February 2026 disclosure; lead plaintiff deadline set for April 13.

Enphase Energy faces class action lawsuit over alleged material misstatements regarding inventory management and tax credit impacts. Lead plaintiff deadline set for April 20, 2026.

$CORT stock plummets 50% after FDA rejects lead drug relacorilant; class action targets alleged disclosure failures with lead plaintiff deadline April 21, 2026.

Navan investors face April 24, 2026 deadline to file lead plaintiff applications in class action over undisclosed $95M sales/marketing expense surge in Q3 2025.